EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort

Arturo Ciccullo iD, Gianmaria Baldin iD, Adriana Cervo, Davide Moschese, Filippo Lagi, Maria Vittoria Cossu, Alessandro Grimaldi, Andrea Giacomelli iD, Stefano Rusconi iD, Gaetana Sterrantino iD, Alberto Borghetti iD, Spinello Antinori iD und 2 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae392 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Arturo Ciccullo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Oxazines, Piperazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We compared the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) and dolutegravir plus lamivudine (DTG + 3TC) in our cohort of treatment-naive people with HIV (PWH).

Methods

In a multicentre cohort of treatment-naive PWH starting a first-line regimen with either dolutegravir plus lamivudine or BIC/FTC/TAF, Kaplan–Meier survival analysis was used to estimate time to virological failure (VF) and time to treatment discontinuation (TD), whereas Cox regression was used to evaluate predictors of VF and TD. Changes in CD4+ cell count were assessed via non-parametric tests, and linear regression analyses were performed to explore predictors of CD4+ cell count changes.

Results

One hundred and seventy individuals were included: 66 started dolutegravir plus lamivudine (DTG group) and 104 started BIC/FTC/TAF (BIC group). During follow-up, we observed two VFs in the DTG group [1.7 per 100 person-years of follow-up (PYFU)] and two in the BIC group (1.7 per 100 PYFU). Estimated probability of remaining free from VF at Week 144 was 95.9% in the DTG group and 95.2% in the BIC group (log-rank P = 0.955). Four TDs were observed in the DTG group (3.4 per 100 PYFU) and 21 in the BIC group (17.6 per 100 PYFU). Estimated probability of maintaining the study regimen at Week 144 was 90.3% in the DTG group and 70.0% in the BIC group; individuals in the BIC group had a higher probability of TD (log-rank P = 0.003). In both groups, the CD4+ count improved significantly during follow-up.

Conclusions

Our study shows that both strategies are effective and safe, with few VFs and TDs due to tolerability issues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPyridonesOxazinesPiperazinesLamivudineHeterocyclic Compounds, 3-RingAnti-HIV AgentsTenofovirEmtricitabineAmidesHeterocyclic Compounds, 4 or More RingsHumansMaleFemaleAdultMiddle AgedCD4 Lymphocyte CountTreatment OutcomeAlanineCohort StudiesAdenineViral LoadAntiretroviral Therapy, Highly ActiveAminobutyratesDrug CombinationsHIV-1Dolutegravir

Substanzen

PyridonesOxazinesPiperazinesLamivudineHeterocyclic Compounds, 3-RingAnti-HIV AgentsTenofovirEmtricitabineAmidesHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Infectious Diseases Unit, San Salvatore Hospital, L'Aquila, Italy.
  • Infectious Diseases Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy.
  • I Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.
  • Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
  • I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milano, Italy.

ORCID-Profile: Arturo Ciccullo, Gianmaria Baldin, Andrea Giacomelli, Stefano Rusconi, Gaetana Sterrantino, Alberto Borghetti, Spinello Antinori

Förderung

  • ViiV Healthcare

Zitieren

APA

Ciccullo, A., Baldin, G., Cervo, A., Moschese, D., Lagi, F., Cossu, M. V., Grimaldi, A., Giacomelli, A., Rusconi, S., Sterrantino, G., Borghetti, A., Antinori, S., Mussini, C., & Di Giambenedetto, S. (2025). Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae392

Vancouver

Ciccullo A, Baldin G, Cervo A, Moschese D, Lagi F, Cossu MV, et al. Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae392

BibTeX
@article{Ciccullo2025,
  author = {Ciccullo, Arturo and Baldin, Gianmaria and Cervo, Adriana and Moschese, Davide and Lagi, Filippo and Cossu, Maria Vittoria and Grimaldi, Alessandro and Giacomelli, Andrea and Rusconi, Stefano and Sterrantino, Gaetana and Borghetti, Alberto and Antinori, Spinello and Mussini, Cristina and Di Giambenedetto, Simona},
  title = {Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae392}
}
Kostenlos starten →